Paper Details

  1. Home
  2. Paper Details

First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors.

Author: FujiwaraYutaka, IwasaSatoru, KitanoShigehisa, KondoShunsuke, KoyamaTakafumi, SatoJun, ShimizuToshio, ShimomuraAkihiko, TamuraKenji, YamamotoNoboru, YonemoriKan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

TAS0313, a novel cancer vaccine cocktail, was evaluated in Japanese patients with advanced solid tumors. The vaccine was well-tolerated and induced immune responses, but the clinical efficacy was limited.
Paper Details　
Original Abstract of the Article :
TAS0313, a novel cancer vaccine cocktail, was developed to overcome the disadvantages of previously developed short and long peptide vaccines; it comprises several long peptides targeting multiple cancer antigens. We evaluated TAS0313 monotherapy in Japanese patients with advanced solid tumors for w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019195/

データ提供：米国国立医学図書館（NLM）

Testing a New Cancer Vaccine: TAS0313

The field of cancer immunotherapy is constantly evolving, with scientists searching for new ways to boost the immune system's ability to fight cancer. This study investigated the potential of a new cancer vaccine called TAS0313 in patients with advanced solid tumors. It's like a new weapon in the fight against cancer!

TAS0313: A New Hope

This vaccine is designed to overcome the limitations of previous cancer vaccines by targeting multiple cancer antigens using a combination of long peptides. This is like a multi-pronged attack on cancer, targeting different vulnerabilities at once. The study found that TAS0313 was well-tolerated and induced immune responses in patients with advanced solid tumors. It's like a first step in building a new fortress to fight off cancer.

The Potential for Future Treatment

While the study did not show significant clinical benefit yet, it sets the stage for further research into the potential of TAS0313 as a treatment for cancer. It's like planting a seed that could blossom into a new hope for cancer patients.

Dr.Camel's Conclusion

This study offers promising insights into the potential of TAS0313 as a cancer vaccine. While further research is needed to determine its clinical efficacy, it provides a glimmer of hope for the future of cancer treatment.

Date :
  1. Date Completed 2021-04-09
  2. Date Revised 2021-04-09
Further Info :

Pubmed ID

33615628

DOI: Digital Object Identifier

PMC8019195

Related Literature

Article Analysis
・Side Effects of pembrolizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.